Curriculum vitae of Lhoëst G.J.J.

 

Surname: Lhoëst

First Name: Georges, J. J.

  Fax:32 2 262415

e-mail .georges.lhoest@skynet.be

website: specmetcrime.com

Lieu et Date de Naissance :  Berchem -Ste-Agathe 20/05/1939  

Nationalité : Belge

  1.Steps in the carreer

  1.1 Doctor of Chemistry,grade obtained in the Department of

    Organic Chemistry,Prof.R.H.Martin (December 1966,ULB)

    Thesis: Title : Structure de la Voacoline et Contribution à l’étude de la Vobtusine

    Field Alkaloid Chemistry

Thèse annexe : La position de condensation du groupe aminométhyle introduit à l’aide de formaldéhyde et d’une amine secondaire sur la tétracycline pourrait être déterminée par l’examen des propriérés physiques et du comportement chimique.

  1.2 Military Service

    Accomplished at the "Belgian Royal Military School". 02.1967-02-1968

 

  1.3 Industry (1968-1971)

    Has been responsible for the "Research Laboratory of theTrimetal Paint Company in Belgium for three years. During his stay in this industry,he got through a two years german language evening course at the "German  School" in Brussels where he obtained his certificate.

    Other languages : Dutch,English,French

  1.4 Catholic University of Louvain (1971-2004),Department of Pharmaceutical  Sciences.

                

1.5 Ministry of Justice

    Professor School of Criminology (1973-1995) Ministry of Justice (High Educational School, HES)

  1.6 Reviewer

    -Cited in the editorial board of Spectroscopy: An International Journal

    - Reviewer for the J.of Chromatography,Biomedical Applications.

    - Reviewer for the Journal of Mass Spectrometry (JMS)

    - Reviewer for Clinical Chemistry

    - editorial board of the review spectroscopy

  1.7 Societies

    Belgian Society of Pharmaceutical Sciences

    Member of the New York Academy of Sciences

    Member of the Dutch Society of Mass Spectrometry

    Member of the French Society for Mass spectrometry

    Member of the German Society for Mass Spectrometry

  1.8 Research interest: Drug Metabolism, Biotranformation and toxicity of immunosuppressive agents (cyclosporin , FK-506, Rapamycin, IMM-125 etc),Structure determination of the metabolites by physico-chemical organic means such as mass spectrometry and NMR spectroscopy and X-ray crystallography (new collaboration with Nancy University (Université Henri Poincaré-UHP as well as with the University of Lille 2)  and evaluation of the reactivity of selected metabolites towards nucleophilic targets as well as their in vitro immunosuppressive activity      (collaboration D. Latinne).   Recently engaged in a CEE project (Environmental Chemistry and Toxicology and possible incidences on the Human Health) Responsible for the Mass Spectrometry Laboratory (Department of Pharm. Sciences) He was received at the Middle Atlantic Mass Spectrometry Center in Baltimore (The Johns Hopkins University) in order to become more familiar with som specific ionization methods in Mass Spectrometry such asFast atom bombardment mass spectrometry and more recently with electrospray mass spectrometry

1.9 Organisation of a Symposium

    SYMPOSIUM GCMS , September 1989

    Shimadzu-UCL (G.Lhoëst).

  1.10    Chairman of a session at International Symposia

  - 2nd International Symposium on the Biological Oxidation of Nitrogen in Organic Molecules, Chelsea College,University of London, September 1977.

-  7th International Symposium on Mass Spectrometry in Biochemistry,Medicine and Environmental Research, Milan, Italy, June 1980

  -  International Congress of Chromatography and Mass Spectrometry in Biomedical Sciences, Bordighera, June 1982.

- International Conference on Developments of  Analytical Methods in Pharmaceutical, Biomedical and Forensic Sciences , University of Verona, Verona, Italy 1986.

1.11  Thèse de Doctorats

         Promoteur de la thèse de Monsieur M. Nickmilder

         Intitulé: Métabolisme et activité immunosuppressive in vitro de la rapamycine.

        défendue le 13 Janvier 1998.

 

2.  PUBLICATIONS  (dans des revues internationales avec évaluation par referee)

2.1 Alcaloïdes Indoliques-Structure de la Voacoline ,  G.Lhoëst et al.  Bull.Soc.Chim.Belges, 74,534-550 (1965)

2.2 Thèse: Structure de la Voacoline et Contribution à l'Etude de la Vobtusine (1966).

2.3 Connaissance des paramètres de solubilité et de quelques aspects de représentation graphique de contours de solubilité de polymères.  G.Lhoëst et Coll. Chimie des Peintures,79,261 (1971).

2.4 Utilisation de certains paramètres physico-chimiques pouvant conduire à une   prévision relative globale des vitesses de diffusion in vitro d'un principe actif solubilisé dans des gels à base de Carbopol.  G.Lhoëst                                                                                                                                                          

 Pharmaceutica Acta Helvetiae,48,549-569 (1973).

2.5 Oxidation routes of Aflatoxin  B1 ,                                                                                      

  G.Lhoëst,P.Dumont,M.Mercier and  M.Roberfroid , Pharmaceutica Acta Helvetiae,50,145-150 (1975).

2.6 Identification by mass spectrometry of a metabolite of Aflatoxin B1            

G.Lhoëst,A.Bettencourt,M.Mercier,P.Dumont and M.Roberfroid.  Pharmaceutica Acta Helvetiae,50,293-297 (1975).

2.7 The importance of certain tautomeric equilibria in the interpretation of mass spectra.                                                                                                                                                                     

  G.Lhoëst and A. Frigerio, Advances in Mass Spectrometry in Biochemistry and Medicine,2,339-349(1976) Spectrum Publication.

2.8 Biological implications of the reaction possibilities of the proximate carcinogenic compound N-hydroxy-2-fluorenylacetamide.                                                                                                            

  G.Lhoëst,C.Razzouk and M. Mercier, Biomed.Mass Spectrometry,3,21-27 (1976).

2.9 Uptake and intracellular localization of morphine in lysozomes and cell sap of cultured fibroblasts.                                                                                                                                       

  M.Liesse,G.Lhoëst,A.Trouet and P.Tulkens,  Arch.Intern.Physiol.Biochimie,84,64 (1976).

2.10 Identification by GCMS analysis of several diazomethanederivatives of phenylglyoxylic acid,an urinary metabolite of styrene, 

G.Lhoëst,J.P.Buchet,R.Lauwerys and M. Mercier,  Pharm.Acta Helv.,51,9,237-242 (1976).

2.11 Isolation and identification by mass spectrometry of metabolites of bupivacaïne,

R.Bouché and G. Lhoëst , Pharm.Acta Helv.,51,7-8,223-225(1976).

2.12 Gas chromatographic and mass fragmentographic assays ofcarcinogenic polycyclic hydrocarbon epoxide hydratase activity.  

A.Bettencourt,G. Lhoëst,M.Roberfroid and M. Mercier, J. of Chromatography, 134, 323-330 (1977).

2.13 Subnanogram estimation of the proximate carcinogen N-hydroxy-2-fluorenylacetamide by gas-liquid chromatography.  

C.Razzouk,G.Lhoëst,M.Roberfroid and M.Mercier, Anal.Biochemistry,83,194-203 (1977).

2.14 Metabolism of benomyl in carrot, strawberry and apple                                          

J.P.Rouchaud,G.J.Lhoëst,M.J.Mercier and  J.A. Meyer,  Pestic. Sci.8,23-30 (1977).

2.15 The proximo-distal carcinogen N-hydroxy-2 fluorenylacetamide,toxification and detoxification routes due to electrophilic and combined 

nucleophilic tautomeric effects ,  

G.Lhoëst,M.Roberfroid and M. Mercier, Biomed.Mass Spectrometry,5,38 (1978).

2.16 Existence of induced nucleophilic tautomerization enzyme allowing the detoxification of the proximo- distal carcinogen N-hydroxy-2-fluorenylacetamide.

G.Lhoëst,M.Mercier ,Biological oxidation of nitrogen,ed.John W. Gorrod Elsevier-North Holland

2.17 Sensitive gas chromatographic methods for the determination of vinyl epoxide synthetase activity using trichloroethylene as a model substrate.                                                                   

E.Malvoisin,B.Rollman,G.Lhoëst,M.Roberfroid and M. Mercier J.of Chromatography,150,345-354 (1978)

2.18 Accessibility of isothermal gas chromatography with wall-coated glass capillary columns,electron capture detection and a solid injector,application to the assay of 2-fluorenylacetamide,  

C.Razzouk, E.Evrard, G.Lhoëst, M.Roberfroid and M. Mercier, J.of Chromatography,161,103-109 (1979).

2.19 The proximo-distal carcinogen of the K region of  benzo(a)pyrene.       

G.Lhoëst        In Recent Developments in Mass Spectrometry in Biochemistry and Medicine,2,179-189 (1979) Elsevier.

2.20 A new synthesis of (S)-(+)-1,5-cyclotrimethylene-3- phenyl-2-thiohydantoin  

J.H.Poupaert and G.Lhoëst       Bull.Soc.Chim.Belges,5,339-343,1979.

2.21 4-Hydroxy-5-oxo-4,5-dihydro-benzo(a)pyrene,a new metabolite of Benzo(a)pyrene                                                                                                               

G.Lhoëst    European Journal of Drug metabolism and Pharmacokinetics,5,41-43 (1980).

2.22 Detection,isolation,preparation of a new metabolite of benzo(a)pyrene and its probable importance in the carcinogenesis process.                                         

G.Lhoëst                                                                                                                                     

In Recent Developments in Mass Spectrometry in Biochemistry and Medicine,6,523-533 (1980) Elsevier.

2.23 Gas Chromatography-Selected Ion Monitoring Applied to the determination of codeine in Plasma,  

G.Lhoëst and M.Mercier, Pharmaceutica Acta Helvetiae,11-12,316-319 (1980).

2.24 A new metabolite of 5,5-diphenylhydantoin containing an epoxide-ol moiety.          

G.Lhoëst,J.H.Poupaert and M.  Claesen, European J.of Mass spectrometry in Biochemistry, Medicine and Environmental Research,1,57-59 (1980).

2.25 Detection of new K and K non K metabolites of benzo(a)-pyrene .            

G.Lhoëst                                                                                                                                                                              

  In Recent Developments in Mass Spectrometry in Biochemistry,Medicine and Environmental Research,  7,99-109 (1981) Elsevier.

2.26 Isolation and Mass Spectrometric Identification of Gitoxin Metabolites excreted in Bile , 

L.N. Kadima,G.Lhoëst and M. LesneEuropean J. of Drug Metabolism and Pharmacokinetics,7, 111-117 (1982).                                                                                                                                                                                        

2.27 Indirect and Direct Identification of N-7-deoxy- ribonucleosides-benzo(a)pyrene K non K region new metabolites adducts,

G.Lhoëst , In Recent Developments in Mass Spectrometry in Biochem , Medicine and Envir.Res.,8,191-202 (1983) Elsevier.

2.28 Mass Spectrometric Evidence of Chemical Interaction of 7,8-benzoflavone with N-hydroxy-2-fluorenylacetamide.  

G.Lhoëst , Chromatography and Mass Spectrometry in Biomedical Sciences,2,387-396 (1983) Elsevier.

2.29 Importance of Collisional Induced Decomposition Mass Spectrometry for the Detection of Tautomeric Forms of a Benzo(a)pyrene New K Region Metabolite.                                         

G.Lhoëst                                                                                                                               

Spectros.Int.J.,3,416-426 (1984).

2.30 Biotranformation of a K Region Metabolite of Benzo(a)- pyrene by Rat and Rabbit Liver Microsomes,  

G.Lhoëst,M.Lesne,D.Dulik and  C.Fenselau , Pharm.Acta Helv. 61,257-260 (1986).

2.31 Biotransformations of a K Region Metabolite of Benzo(a)pyrene,   

G.Lhoëst,J.De Graaf and J.Van Cantfort ,

Development of Analytical Methods in Pharmaceutical, Biomedical and Forensic Sciences,169-181 (1987)Plenum Press (New York).

2.32 Isolation and Identification of a dihydrodiol and of different synthetic pseudoepoxides of cyclosporin A by  FAB Mass Spectrometry and NMR Spectroscopy,  

G.Lhoëst,P.Wallemacq,P.Dumont and G.Van Binst, Spectros.Int. J. 6, 269-282 (1988).

 2.33 Isolation,Purification and Structure Elucidation of Cyclosporin A metabolites in Rabbit and Man,  P.E.Wallemacq,

G.Lhoëst and P.Dumont, Biomed.and Envir.Mass Spectrometry,18,48-56 (1989).

2.34 Isolation,Characterization and in Vitro Activity of Human Cyclosporin A Metabolites,  

P.E.Wallemacq, G.Lhoëst, D.Latinne and M.De Bruyère, Transplantation Proceedings,21,1,906-910 (1989).

2.35 Crossreactivity of Cyclosporine Metabolites in two Different Radioimmunoassays using the Specific monoclonal Antibody ,

P.E.Wallemacq,S.C.Lee,G.Lhoëst and A.Hassoun, Clin Chem., 36, 385 (1990).

2.36 Isolation and Mass Spectrometric Identification of Five Metabolites of FK-506,a   Novel  Macrolide Immuno-suppressive Agent,from Human Plasma,  

G.Lhoëst,P.E.Wallemacq and R.K.VerbeeckPharmaceutica Acta Helvetiae , 66, 11, 302-306 (1991).

2.37 Metabolites of FK-506,  

G.Lhoëst, R.Verbeeck  British Patent Application n° 9113915.4 (1991).

2.38. A combined HPLC-ELISA evaluation of FK-506 in transplant patient,  

M.C. Friob, A. Hassoun, D. Latinne, G. Lhoëst, B. Otte and P.A. Wallemacq, Transplantation Proceedings, 23, 2750-2752 (1991).

2.39 Isolation and Mass Spectrometric identification of two metabolites of FK-506 from rat liver microsomal incubation media, 

G. Lhoëst, N. Maton and R.K. Verbeeck, Pharm. Acta Helv.   67, 9-10, 270-274 (1992).    

2.40 Isolation and Mass Spectrometric Identification of cyclosporin An Isomeric Dihydrodiol Precursors from Erythromycin-Induced Rabbit Liver Microsomes,  

M. Nickmilder, R.K. Verbeeck and G. Lhoëst, Pharm. Acta Helv. 67, 9-10, 275-281 (1992).

2.41 Isolation and identification by FAB Mass Spectrometry and NMRSpectroscopy of a Demethylated Metabolite of FK-506 from Erythromycin-induced Rabbit Liver Microsomes ,

 G. Lhoëst, N. Maton and R. Verbeeck, Pharm. Acta Helv.  68, 35-41 (1993).

2.42 Isolation and Identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin induced rabbit liver microsomes, G. Lhoëst, N. Maton and R.K. Verbeeck , 

Drug Metabolism and Disposition, 21, 850-854 (1993).

2.43  Isolation and identification of a FK-506 C36-C37 dihydrodiol from erythromycin induced rabbit liver microsomes,   

G. Lhoëst, N. Maton, A. Laurent and R.K. Verbeeck , J. of Pharmaceutical & Biomedical Analysis, 12, 235-241 (1994).

2.44 Characterization of a FK-506 C36-C37 dihydrodiol from erythromycin induced rabbi liver microsomes: In vitro evaluation of immunosuppressive activities of synthetic analogues,   

G. Lhoëst, N. Maton, A. Laurent, R.K. Verbeeck, D. Latinne, In Mass Spectrometry in Cancer Research,  pp 164-182 (1994) edited by E Constantin, Amudes Strasbourg, France.

2.45 15-Desmethyl FK-506 and 15-31-Desmethyl FK-506 from human liver microsomes: Isolation, Identification (by Fast Atom Bombardment Mass Spectrometry and NMR), and Evaluation of in Vitro Immunosuppressive Activity,  

G. Lhoëst, N. Maton, D. Latinne, A. Laurent, R.K. Verbeeck, Clinical Chemisry, 40, 740-744 (1994).

2.46  The in Vitro Immunosuppressive Activity of the C15 -demethylated Metabolite of FK-506 is Governed by Ring- and Open-Chain Tautomerism Effects ,  

G. Lhoëst, R.K. Verbeeck, N. Maton, P. Muthelet, D. Latinne , J. of Pharm. and Exp. Ther., 274, 622-626 (1995).

2.47 Dérivés de l'acide pipécolique destinés au traitement et/ou à la prévention thérapeutique - Brevet                         

G. Lhoëst, D. Latinne, PUCL. 47.BE (1995).

2.48. Isolation and identification of new rapamycin dihydrodiol metabolites from dexamethasone induced rat liver microsomes.

M.J.M. Nickmilder, D. Latinne, R.K. Verbeeck, W. Janssens, D. Svoboda and G. Lhoëst , 

Xenobiotica, 27, 869-883 (1997)

2.49. Identification and in vitro immunosuppressive activity of a SDZ-IMM-125 metabolite  isolated from phenobarbital -induced rabbit liver microsomes, 

R. Dieden, R.K. Verbeeck, N. Maton, D. Latinne and G.J.J. Lhoëst , Xenobiotica, 27, 933-949 (1997).

2.50  Isolation and Identification by LC-MS/MS of two new FK-506 metabolites from pig liver microsomes,                  

G.J. J. Lhoëst, R.K. Verbeeck, N.J. Maton, D.M. Latinne,  accepté pour publication dans Advances in Mass Spectrometry, Book  with CDROM  resulting from accepted articles at the 14th International Mass Spectrometry Conference (1998) Tampere, Finland  1997.  Published November Vol 14, p 142 (1998).

2.51. In vitro immunosuppressive activity, isolation from pig liver microsomes an identification by electrospray ms-ms of a new FK-506 C19-C20 epoxide metabolite

G. Lhoëst, R. Dieden, R.K. Verbeeck, N. Maton, A. Ingedoh and D. Latinne

J. Pharm. and Exp. Ther. 284, 1074-1081 (1998)

2.52  Identification and in vitro immunosuppressive activity of a rapamycin demethylated metabolite isolated  from pig liver microsomes,  

M.J.M. Nickmilder, D. Latinne, R.K. Verbeeck, Dieden R. and G. Lhoëst, Clin. Chem.  44(3), 532-538 (1998).

2.53  Isolation, Identification, Immunosuppressive activity of a new SDZ-IMM-125metabolite from Human Liver Microsomes.  Identification of its cyclophilin A-IMM-125 metabolite complex by nanospray LC-ms/ms mass spectrometry,  

G. Lhoëst, A.P.J.M. de Jong, H.D. Meiring, N. Maton, D. Latinne, R.K. Verbeeck, J.B. Otte and M. Zurini, J. of Mass Spectrometry  33, 936-942 (1998).

2.54  Isolation from pig liver microsomes, Identification by Tandem Mass Spectrometry and in vitro immunosuppressive activity of a new rapamycin tris-epoxide metabolite,  

G. Lhoëst, T.Zey, R.K. Verbeeck, P. Wallemacq, N. Maton, J.P. Dehoux and D. Latinne, J. of Mass Spectrometry  34, 28-32 (1999).

2.55  Isolation, identification and immunosuppressive activity of SDZ-IMM-125 metabolites  from human liver microsomes,  

R. Dieden, R.K. Verbeeck, D. Latinne, P. Wallemacq, N. Maton and G.J.J. LhoestEur. J. Drug Metab. and Pharmacokinetics 24, 83-90 (1999).

2.56.  Isolation from pig liver microsomes, identification by tandem mass spectrometry and in vitro immunosuppressive activity of a SDZ-RAD 17,18-19,20-21,22 tris-epoxide,

G.J.J. Lhoëst, T.Y.R. Gougnard, R.K. Verbeeck, N. Maton, J.P. Dehoux, P. Wallemacq, W. Schüler and D. Latinne, J. Mass Spectrom.  35 (2000),  454-460      IF 3.2

2.57  Cyclization reactions of IM-125 and oxidation of cyclosporin A amino-acid 1 in the a position of the of the double bond lead to the loss of in vitro immunosuppressive activity,

  R. Dieden, D. Latinne, C. Baldari, N. Maton, A. Aubry, R.K. Verbeeck, M. Zurini and G.J.J. Lhoëst, Spectroscopy  14 ,  215-228 (2000).   IF 0.627

2.58 Isolation from rat urine and human liver microsomes and identification by Electrospray and nanospray tandem mass spectrometry of new malagashanine metabolites,  

H. Rafatro, R.K. Verbeeck, T.Y.R. Gougnard, P.J.M. De Jonghe, P. Rasoaanaivo, A. Laurent and G. Lhoëst,  J. Mass Spectrom. 35, 1112-1120 (2000).  IF 3.2

2.59. In vitro immunosuppresive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry.  

G. Lhoëst, R. Hertsens, R.K. Verbeeck, N. Maton, P. Wallemacq, J.P. Dehoux and D. Latinne,   J. Mass Spectrom.   36, 889-901 (2001).

2.60  In vitro immunosuppressive activity of the two main tautomers of the 4,5-ketol derivative of benzo(a)pyrene,  R. Dieden, D. Latinne, R. Hertsens, N. Maton, C. Van Haluwijn and G.J.J. Lhoëst ,  submitted for publication     

 

3. ABSTRACTS :  Communications Internationales

3.1 Connaissances des paramètres de solubilité et de quelques aspects de représentation graphique de contours de solubilité de polymères.                                                                                                                                            

G.Lhoëst   

Communication présentée à L'A.T.I.P.I.C (1971). Conference Oral communication

3.2 Quelques applications de la spectrométrie de masse dans le domaine biomédical                                                                          

G.Lhoëst and M.Mercier                                                                                                                                                  

Faculté de Médecine de Dijon (1975). Oral communication

3.3  The importance of certain tautomeric equilibria in the interpretation of mass spectra                                                                                                                                                                       G.Lhoëst                                                                                                                                                                               

3rd International Symposium on Mass Spectrometry in Biochemistry and Medicine,Alghero,Sardinia (1975).   Oral communication

3.4 Some features in the chemistry of N-hydroxy-2-fluorenyl- acetamide enlarging the concept of proximate and distal carcinogens.                                                                                                                                                              

G.Lhoëst and M.Mercier                                                                                  

  International Symposium on Mass Spectrometry in DrugMetabolism (Mario Negri Institute,Milan,1976). Oral communication

3.5 The proximo-distal carcinogen N-hydroxy-2-fluorenyl-acetamide and some detoxification routes                                                                                                                                                                  G.Lhoëst                                                                                                                                                                               

4th International Symposium on Mass Spectrometry in Biochemistry and Medicine(Riva Del Garda) 1977. Oral communication 

3.6 Réactions d'activation et de désactivation du N-hydroxy- 2-acétyl-aminofluorène, 

G.Lhoëst,  Société Belge de Biochimie à Louvain-en-Woluwe,Ecole de Pharmacie (1977). Oral communication

3.7 Existence of induced nucleophilic tautomerization enzyme allowing the detoxification of the proximo-distal carcinogen N-hydroxy-2-fluorenylacetamide.  

G.Lhoëst and M.Mercier,  

2nd International Symposium on the Biological Oxidation of Nitrogen in Organic Molecules,Chelsea College, University of London,September 1977. Oral communication.  L'intéressé y a également tenu le rôle de chairman de session. Il y a reçu parmi d'autres une médaille avec effigie de la reine pour contribution appréciée.

3.8 The proximo-distal carcinogen of the K region of benzo(a)pyrene.            

G.Lhoëst                                                                                                                                                                              

5th International Symposium on Mass Spectrometry in Biochemistry and Medicine,Rimini,June 1978. Oral communication

3.9 Detection,isolation and preparation of a new metabolite of benzo(a)pyrene and its probable importance in the carcinogenesis process.                                     

G.Lhoëst                                                                                                                                                                             

  6th International Symposium on Mass Spectrometry in Biochemistry and Medicine,Venice,Italy,June 1979.  Oral communication

3.10 Reactivation by rat liver microsomes of 4-hydroxy-5-oxo-4,5-dihydro-benzo(a)pyrene                                                                                                       G.Lhoëst                                                                                                                                                                

International Liquid Chromatography Symposium 5, Amsterdam,RAI Congress Center,April 1980.  

3.11 Isolation and identification of non-K-region new metabolites of benzo(a)pyrene from rat liver microsomes.                                                                                 

G.Lhoëst                                                                                                                                                                              

7th International Symposium on Mass Spectrometry in Biochemistry,Medicine and Environmental Research, Milan,Italy,June,1980. Oral communication. L'intéressé y a également tenu le rôle de chairman de session.

3.12 Detection of K and non K metabolites of benzo(a)pyrene                                                                           

G.Lhoëst                                                                                                                                                                        

Second International Congress on Toxicology,Mechanisms of Toxicity and Hazard Evaluation,Patron:His Majesty the King of Belgium,Brussels,July 1980. Oral communication

3.13 Indirect and Direct identification of N7-deoxy-ribonucleosides-benzo(a)pyrene K non K region metabolites adducts                                                                                                                                                             G.Lhoëst                                                                                                                                                                             

  8th International Symposium on Mass spectrometry in Biochemistry,Medicine and Environmental Research, Venice,June 1981.  Oral communication

3.14 Mass Spectrometric Evidence of Chemical Interaction of 7,8-benzoflavone with N-hydroxy-2-fluorenylacetamide                                                                                                                          G.Lhoëst                                                                                                                                                               

  International Congress of Chromatography and Mass Spectrometry in Biomedical Sciences,Bordighera, June 1982.  Oral communication

L'intéressé y a également tenu le rôle de chairman de session.

3.15 Importance of Collisional Induced Decomposition Mass Spectrometry for the Detection of Tautomeric Forms of a Benzo(a)pyrene New K Region Metabolite.           

G.Lhoëst                                                                                                                                                                             

  2nd International Conference on Chromatography and Mass Spectrometry in Biomedical Sciences,June 1984, Milan. oral communication

3.16 Detection of New K and K non K Metabolites of Benzo(a)pyrene              

G.Lhoëst                                                                                                                                                                         

  Abel Library,302 Wood Basic Science Building,August 7 1984.  The John Hopkins University,School of Medicine , Baltimore,USA   oral communication

3.17 Biotransformation of a K region metabolite of benzo(a)- pyrene by rat and rabbit liver microsomes.                                                                                                                                                              

G.Lhoëst, M.Lesne,D.Dulik,C.Fenselau                                                                                                                              

10th International Mass Spectrometry Conference, September 1985,Swansea,UK.

3.18 In vitro biotranformations of a K region metabolite of benzo(a)pyrene by rat and human liver microsomes.                                                                                                                                            

G.Lhoëst,M.Lesne,J.De Graeve and J.Van Cantfort                                                                                             

  Developments in Analytical Methods in Pharmaceutical, Biomedical and Forensic Sciences,Université de Verona, June 1986,Italy. Oral communication.   L'intéressé y a également tenu le rôle de chairman de  session et a reçu une médaille de Congrès.

3.19 Biotransformations of a K region metabolite of benzo(a)pyrene by different animal species including man.    

G.Lhoëst, J.De Graeve and J.Van Cantfort ,

International Symposium on Applied Mass Spectrometry in the Health Sciences,Barcelona,September,1987.

3.20 Isolation and structure elucidation of cyclosporine metabolites                                                                

P.E.Wallemacq and G.Lhoëst ,  

International Symposium on Applied  Mass Spectrometry in the Health Sciences, Barcelona,September 1987,last minute communication.  

3.21 Biotransformations of a K region metabolite of BaP by different animal species including manG.Lhoëst, J.De Graeve and J.Van Cantfort , 11th International Mass Spectrometry Conference ,Bordeaux,Aug-Sept.1988.

3.22 Isolation,detection and structure elucidation of cyclosporin A metabolites in rabbit perfused liver and man. 

  P.E.Wallemacq and G.Lhoëst ,

11th International Mass Spectrometry Conference , Bordeaux,Aug-Sept.1988.

3.23 Isolation,identification and in vitro activity of human cylosporine metabolites,   

P.E Wallemacq, G.Lhoëst and D.Latinne ,

12th International Congress of the Transplantation Society,3,1988.

3.24 Identification of dihydrodiols and pseudo-epoxides of cyclosporin A,   

G.Lhoëst, P.E.Wallemacq and R.K.Verbeeck,  

49th International Congress of Pharmaceutical Sciences of FIB,Munich,September 1989,Germany.

3.25 Spectrométrie de masse et métabolisme du benzo(a)pyrene, 

G.Lhoëst  , Symposium GCMS, Shimadzu-UCL, Septembre 1989.  keynote lecture oral communication

3.26 A new potentially toxic metabolite of cyclosporin A;Biotransformation and toxicity, 

  P.E Wallemacq and G.Lhoëst  Beltox meeting (1990).

3.27 Mass Spectrometric and NMR identification of dihydrodiols and pseudo-epoxides of ciclosporin 

G.Lhoëst, P.E.Wallemacq and R.K.Verbeeck,  

2nd International Symposium on Applied Mass Spectrometry in the Health Sciences,Barcelona 1990.

3.28 A specific serum evaluation of the FK-506 in transplant patients , 

  M.C Friob,A.Hassoun,G.Lhoëst,J.B.Otte and P.E.Wallemacq

3rd Forum of the Pharmaceutical Sciences (Belgian Society of the Pharmaceutical Sciences),Houffalize 1991.

3.29 Isolation and Mass Spectrometric Identification of Metabolites of FK-506 from Human Plasma,

G.Lhoëst, P.E.Wallemacq and R.K.Verbeeck,

12th International Mass Spectrometry Conference,1991, IMSC 91) Amsterdam,Holland,Abstract TuA-C27 page 132.

3.30 Isolation and Mass spectrometric Identification of several metabolites of a novel immunosuppressive agent, FK-506,from human plasma and whole blood.  

G.Lhoëst, M.Friob,P.Wallemacq,R.Verbeeck and J.B.Otte,                 

Réunion Commune des Sociétés de Pharmacie Françaises et Allemande Strasbourg,19-22 (1991),Abstract P 91 page 747.

3.31 Metabolic dihydrodiol precursors of cyclosporin A,  

G. Lhoëst,  M. Nickmilder and R. Verbeeck,  

1st European Congress of Pharmaceutical Sciences, 7-9 October 1992   Amsterdam, The Netherlands Abstract 031/PW70 page 28.

3.32 Characterization of a FK-506 C36-C37 Dihydrodiol from Erythromycin Induced Rabbit Liver Microsomes : In Vitro Evaluation of Immunosuppressive Activities of Synthetic Analogues.

  G. Lhoëst,  N. Maton, A. Laurent, R.K. Verbeeck, D. Latinne,T

Therapeutic Aspects and Analytical Methods in Cancer Research, Mass Spectrometry in Cancer Research, Symposium, Strasbourg France , Juillet 1993 . oral communication  

3.33 Isolation and Identification by FAB Mass Spectrometry and NMR Spectroscopy ofFK-506 Demethylated Metabolites from Human Liver Microsomes: Evaluation of their in Vitro Immunosuppressive  Properties ,  

  G. Lhoëst, R.K. Verbeeck, N. Maton, P. Muthelet and D. Latinne,  

5th International Symposiumon Pharmaceutical and Biomedical Analysis , September   21-24, 1994, Stockholm, Sweden . oral communication

3.34  A new metabolite  of rapamycin, isolated from dexamethasone induced rat liver microsomes, was found to be a compound where rapamycin's conjugated double bond system was modified.   

M. Nickmilder, R. Verbeeck, D. Latinne and G. Lhoëst , 

5th International Symposium on Drug Analysis, 12-15 September 1995, Leuven 

3.35. De la spectrométrie de masse d'un métabolite C15- déméthylé du FK-506 a l'ébauche conceptuelle d'une nouvelle classe de médicaments immunosuppresseurs.  

G.Lhoëst, R.K. Verbeeck, N. Maton, D. Latinne,  

XII ème Journées Françaises de Spectrométrie de Masse, 11-14 Septembre 1995, Bordeaux. Abstract  O-12 Page 80, communication orale.

3.36 Isolation from Phenobarbital induced rabbit liver microsomes, identification and in vitro immunosuppressive activity of three SDZ-IMM-125 metabolites.  

G. Lhoëst, R. Dieden, N. Maton, R.K. Verbeeck and D. Latinne

 Sixth Stowe Symposium on Drug Metabolism, July 17-20, 1996.  Stoke Rochford Hall near Grantham, England. Poster 38.  Organized by the UK Drug Metabolism Group

3.37. Isolation and identification of two new rapamycin dihydrodiol metabolites from dexamethasone induced rat liver microsomes.

  M. Nickmilder, D. Latinne, R.K. Verbeeck and G. Lhoëst , 

Sixth Stowe Symposium on Drug Metabolism, July 17-20, 1996.  Stoke Rochford Hall near Grantham, England. Poster 39. Organized by the UK Drug Metabolism Group

3.38 Identification et activité immunosuppressive in vitro de trois métabolites du SDZ-IMM-125. Analogie structurale avec un métabolite du FK-506 et domaine de liaisons à leurs immunophilines.  

Lhoëst G.J.J., Dieden R.,. Maton N., Verbeeck R.K. and Latinne 

D.M.G, 13 ièmes Journées françaises de spectrométrie de masse, 17-19 septembre 1996, Orléans    communication orale.

3.39 Métabolisme de l'IMM-125, du FK-506 et de la Rapamycine et domaines de liaison à leurs immunophilines.           

G. Lhoëst Nancy, 7 Février 1997. 

Conférence présentée  en la salle des thèses de l'Université Henri Poincaré Nancy I.

3.40 Isolation and Identification by LC-MS/MS of two new FK-506 metabolites from pig liver microsomes ,

G. J.J.  Lhoëst, R.K. Verbeeck, N. J.Maton, D.M. Latinne , 

communication présentée à "14th International Mass Spectrometry Conference 25-29 Aout 1997, Tampere, Finland."

3.41  Identification et activité immunosuppressive d'un nouveau métabolite du SDZ-IMM-125 isolé à partir de microsomes de foie humain.  Identification du complexe cyclophilin A-metabolites par nanospray ms/ms.

Lhoëst G.J.J., De Jong A.P.J.M., Latinne D., Verbeeck R.K., Zurini M. 

15eme Journées Françaises  de Spectrométrie de Masse, Septembre 1998 ,Abstract page 127 Lyon .

3.42. Identification et activité immunosuppressive in vitro d’un nouveau métabolite du SDZ RAD isolé à partir de microsomes de foie de porc

G. Lhoëst, R.K. Verbeeck, N. Maton et D. Latinne. 1

6eme Journées Françaises de Spectrométrie de Masse , Nancy  Palais des Congrès 6-9 Septembre 1999.

3.43  Isolation from pig and human liver microsomes, identification by ESI-MS/MS and in vitro immunosuppressive activity of different SDZ-RAD epoxide metabolites.   

G.J.J. Lhoëst, R.C. Hertsens, R.K. Verbeeck, N.J. Maton, D.M. Latinne, 

15th International Mass Spectrometry Conference (Barcelona)  August 27  September 1, 2000 Page 174

3.44  Isolation from rat urine and human liver microsomes, identification by electrospray  mass spectrometry of new malagashanine metabolites.                                                                                                                                            

R.C. Hertsens, G. Lhoëst, R.K. Verbeeck, H. Rafatro                                                                                                          

15th International Mass Spectrometry Conference ( Barcelona)  August 27  September 1, 2000 Page 172.

3.45  Activité immunosuppressive in vitro de précurseurs dihydrodiols du FK506 et identification de ces composés par spectrométrie de masse. 

  G.J.J. Lhoëst, R. Hertsens, R.K. Verbeeck, N. Maton, D. Latinne. 

18èmes Journées françaises de Spectromètrie de Masse  La Rochelle 11-14 Septembre 2001  Poster 81 p 143.

3.46  Tautomerism and Oxidation of Xenobiotics ,

G.J.J. Lhoëst, Hertsens R. Dieden R, Latinne D.  

Deutsche Gesellschaft für Massen Spectrometrie  DKFZ  Heidelberg  März 2002  communication orale.

3.47 .    In vitro immunosuppressive activity of the two main tautomers of an Environmental

         contaminant the 4,5-ketol derivative of benzo(a)pyrene.

         G. J. J. Lhoëst, R.C. Hertsens, R. D. Dieden, C. M. Van Haluwijn, D. N. Latinne

         A conference co-organized by the University of Geneva and the Swiss Federal  l

         Institute of Technology , Lausanne , under the aegis of the European Association of

         Chemistry and the Environment .

        Abstract OPAN-7 page 58

 

3. 48 Tautomérie, Métabolisme et Intéraction FK-506-FKBP-12

           G.J.J.  Lhoëst, R. Hertsens et D. Latinne

            Spectrométrie de Masse et Analyse Protéomique,  20 ème Journées Françaises de

            Spectrométrie de Masse,  Toulouse 16-19 Septembre, Centre de  Congrès Pierre Baudis 

            2003, Abstract P123  page 219.

 3.49. Potential New Immunosuppressive Drugs Derived from Sanglifehrin A and Detected by ESI+-TOF/MS

           G.J.J.  Lhoëst, R. Hertsens, H. Ikami, D. Latinne, M. Zurini and R. Sedrani.

          21ème symposium de Spectrométrie de Masse , 14-17 Septembre 2004, Palais des Congrès de Strasbourg

 

3.50  Désorptions laser et ionique pour l'analyse FTICR-MS et l'imagerie par ToF-MS

          Journée scientifique du 7 novembre 2005 à l'université Paul Verlaine, Metz

          participation à cette journée

 

3.51  Introduction du design d'un nouveau type de spectromètre de masse

           G. J. J. Lhoëst

           23ème JFSM  du 11 au 14 Septembre 2006 à la Cité des Congrès de Nantes